GlassScriptPhysician profile
Bassel Noumi
NPI 1932497856
$7,534.95
in general payments reported to CMS, 2019-2025
36 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $575 · 2021: $472 · 2022: $692 · 2023: $800 · 2024: $1,519 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,699 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,698.72 |
| Education | $320.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,405.39 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $2,331.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.44 | 2019-2025 | Ofev, Spiriva Respimat |
| Philips North America LLC | $274.46 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $239.21 | 2019-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $203.16 | 2023-2025 | |
| Inspire Medical Systems, INC. | $194.90 | 2024-2025 | Inspire |
| Insmed, INC. | $134.77 | 2019-2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $120.65 | 2025 | Sunosi |
| Mylan Specialty L.P. | $114.72 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $102.07 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $91.27 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| United Therapeutics Corporation | $81.61 | 2023-2025 | Tyvaso, Tyvaso |
| Covidien LP | $70.91 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $66.11 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $63.13 | 2020-2025 | Dupixent |
| Advanced Respiratory, INC | $53.36 | 2020-2021 | |
| Vifor Pharma, INC. | $47.87 | 2024-2025 | Zemaira |
| Novartis Pharmaceuticals Corporation | $45.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.79 | 2020 | |
| Verona Pharma, INC. | $34.29 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $32.39 | 2025 | Zepbound |
| Circassia INC. | $31.02 | 2019 | |
| Itamar Medical INC | $29.14 | 2024 | Watchpatone |
| Gilead Sciences, INC. | $28.88 | 2021 | |
| Genentech USA, INC. | $23.08 | 2020 | |
| Grifols USA, LLC | $21.91 | 2025 | Prolastin-C Liquid |
| Olympus America INC. | $20.37 | 2022 | |
| Veran Medical Technologies, INC. | $19.37 | 2020 | |
| Baxter Healthcare | $18.48 | 2025 | Hillrom - Monarch Airway Clearance System |
| Zoll Respicardia, INC. | $16.24 | 2025 | Remede System |
| Electromed, INC. | $14.94 | 2025 | Smartvest |
| Optinose US, INC. | $14.52 | 2020 | |
| Kaleo, INC. | $13.85 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Noumi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.